Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Ocugen reports strong Q3 progress with key approvals and financial stability

Ocugen's Q3 2024 earnings call highlighted notable achievements in clinical advancements, regulatory approvals, and financial stability, positioning the company for future growth.
With a focus on advancing key pipeline candidates and managing expenses effectively, Ocugen aims to capitalize on opportunities for expansion and partnership collaborations.
While facing challenges in meeting timelines and ensuring successful trial outcomes, Ocugen remains optimistic about the potential of its innovative therapies to address unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lucid Group

Rivian Automotive

These hypergrowth stocks are expected to deliver up to 1,075% sales growth this year.

3 of the Fastest-Growing Stocks on the Planet in 2023

Bionano Genomics

Opendoor

Select analysts expect these small-caps stocks to catapult higher in the new year.

3 Under-the-Radar Stocks With 590% to 772% Upside in 2023, According to Wall Street

Coinbase

Mullen Automotive

Procter & Gamble

Starbucks

Silvergate Capital Corp

Workhorse Group

In 2022, I was able to greatly reduce my stock portfolio's losses by shorting several U.S. equities. I found it fairly easy to find favorable stocks to short, as the valuations of many companies were ridiculously high last year, and many stocks were pricing in scenarios that almost certainly would never materialize.

7 ‘Loser' Stocks to Short for Big Profits

Ocugen (NASDAQ: OCGN ) stock jumped nearly 20% over the weekend following positive results for its Covid-19 vaccine in the U.S. OCGN stock has since dropped back down to about 2% up during the morning's trading session. The company hopes to commercialize a traditional vaccine made by Bharat Biotech of India: Covaxin.

Why Is Ocugen (OCGN) Stock Up Today?

CureVac B.V

Moderna

A flurry of announcements relating to COVID vaccines dominated headlines on the pandemic on Monday, with Moderna telling investors it expects to generate some $5 billion in sales in 2023.

Moderna, CureVac and Ocugen offer updates on COVID vaccines, while China cracks down on critics of government's pandemic response

Context Therapeutics LLC

Kronos Bio

Sonnet BioTherapeutics

Instil Bio

Hot penny stocks to watch with news this week. The post 5 Hot Penny Stocks To Watch This Week With Big News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Hot Penny Stocks To Watch This Week With Big News

Ocugen Inc. stock OCGN, +0.78% rallied 16% in premarket trade Monday, after the biopharma company announced positive results in a trial of its COVID vaccine Covaxin. The Phase 2/3 trial involved 491 U.S. adult participants who receive two doses of Covaxin or placebo 28 days apart.

Ocugen stock up 16% premarket after company announced positive results for its COVID vaccine

MALVERN, Pa., Jan. 09, 2023 (GLOBE NEWSWIRE) -- , Inc. (Ocugen) (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced positive results from the Phase 2/3, observer-blind, immuno-bridging and broadening study of its COVID-19 vaccine candidate, COVAXIN™ (BBV152; Clinicaltrials.gov, NCT05258669), a whole-virion inactivated COVID-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades. COVAXIN™, an inactivated virus vaccine adjuvanted with TLR7/8 agonist, has been demonstrated in clinical trials to generate a broader immune response against the whole virus covering important antigens such as S-protein, RBD, and N-protein; whereas currently approved vaccines in the U.S. target only S-protein antigen. Additionally, in contrast to other inactivated vaccines, clinical trials have demonstrated that TLR7/8 agonist adjuvant in COVAXIN™ generates a Th1-biased immune response that induces robust long-term memory B- and T-cell responses.

Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met

Could short-sellers be enacting a squeeze?

Why Shares of Ocugen Jumped Thursday

AMC Entertainment

Bed Bath & Beyond

GameStop

Skillz

As we enter the new year, it's time to go through your portfolio and discover which meme stocks to sell. In many ways, I believe that 2022 can be viewed as the year of “the baby and the bathwater” for U.S. stocks.

7 Hot Meme Stocks of 2022 to Sell Before 2023

There's a tug-of-war going on today with Ocugen (NASDAQ: OCGN ) stock between the buyer and sellers. The sellers have taken the lead, however, despite apparently positive news.

OCGN Stock Alert: What to Know About Ocugen's Latest Phase 3 Clinical Trial

Important next step for Ocugen's regenerative cell therapy in orthopedics since announcing pipeline expansion in May 2022 Important next step for Ocugen's regenerative cell therapy in orthopedics since announcing pipeline expansion in May 2022

Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®

U.S. Food & Drug Administration (FDA) acknowledges the potential of OCU400 to treat rare inherited retinal diseases U.S. Food & Drug Administration (FDA) acknowledges the potential of OCU400 to treat rare inherited retinal diseases

Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosis

MALVERN, Pa., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen, along with the Board of Directors and Executive Management Team, will ring the Nasdaq Closing Bell on Monday, December 19, 2022.

Ocugen, Inc. to Ring the Nasdaq Stock Market Closing Bell

Continued Positive Safety Data for OCU400

Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis

MALVERN, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company's Chief Scientific Officer, Arun Upadhyay, Ph.D., will participate in the 3 rd Annual Dry AMD Therapeutics Summit at the Revere Hotel in Boston, Mass. from November 30-December 2, 2022.

Ocugen to Present at 3rd Annual Dry AMD Therapeutics Summit

Biogen

Inovio Pharmaceuticals

Even though many stocks have fallen sharply in price, not all are bargains -- investors must remains selective.

3 Stocks to Avoid Right Now

A prognosticator got less bullish on the company's prospects, and investors took this to heart.

Why Ocugen Stock Wilted on Wednesday

A third-quarter report, complete with clinical updates, is more than enough to satisfy the biotech's bulls.

Why Ocugen Stock Popped by 7% on Tuesday

Ocugen, Inc. (NASDAQ:OCGN ) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Tiffany Hamilton - Head, Corporate Communications Shankar Musunuri - Chairman, Chief Executive Officer & Co-Founder Jessica Crespo - Chief Accounting Officer & Senior Vice President, Finance Conference Call Participants Jennifer Kim - Cantor Fitzgerald Robert LeBoyer - Noble Capital Daniil Gataulin - Chardan Jonathan Aschoff - ROTH Capital Partners Uy Ear - Mizuho Securities Operator Good morning and welcome to the Ocugen Third Quarter 2022 Business Update and Financial Results Call. At this time, all participants are in a listen-only mode.

Ocugen, Inc. (OCGN) Q3 2022 Earnings Call Transcript

Conference Call and Webcast Today at 8:30 a.m. ET

Ocugen Provides Business Update & Third Quarter 2022 Financial Results

Tesla

Select analysts and pundits foresee game-changing upside from this fast-paced trio.

3 High-Octane Growth Stocks With 357% to 571% Upside, According to Wall Street

Himax Tech

Hyzon Motors

Peloton

Redfin

Vroom

Financial markets have been in turmoil for the better part of the past six months. The stock market has plunged to new lows as the Federal Reserve tightens the screws with rampant interest rate hikes.

Warning! Don't Even Consider Buying These 7 Dead-Money Stocks

MALVERN, Pa., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to discuss the Company's third quarter 2022 financial results and provide a business update at 8:30 a.m. ET on Tuesday, November 8, 2022.

Ocugen to Host Conference Call on Tuesday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial Results

Highlighting Ocugen research and innovative technologies

News for Ocugen, Inc. Stock (OCGN)